Korea Weight Loss Diet Market Size & Outlook, 2026-2034
Korea Weight Loss Diet Market Insights
- As per Deep Market Insights insights, the Korea Weight Loss Diet Market stood at USD 4.11 Billion in 2025 and is anticipated to grow to USD 7.67 Billion by 2034.
- The Korea market is expected to advance at a CAGR of 7.15% from 2026 through 2034.
- In 2025, Meal Replacement Plans accounted for the highest share of the By Product Type market size.
- During the forecast period, Keto Diet Programs is set to register the highest growth, making it the most lucrative By Product Type segment.
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Korea represented 1.47% of the overall global Weight Loss Diet Market size.
- United States is projected to lead the global Weight Loss Diet Market size by 2034.
- Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2034.
- India is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 32.3 Billion by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 4.11 Billion |
| Market Size In 2034 | USD 7.67 Billion |
| Largest segment | Meal Replacement Plans |
| Units | Revenue in USD Billion |
| CAGR | 7.15% (2026-2034) |
| Segmnetation Covered | |
| By Product Type |
|
| By End-Use |
|
| By Distribution Channel |
|
| By Price Range |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Korea Weight Loss Diet Market By Product Type 2026-2034 (USD Billion)
| By Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meal Replacement Plans | XX.x | XX.x | XX.x | 1.87 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Keto Diet Programs | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Intermittent Fasting Plans | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Korea Weight Loss Diet Market By End-Use 2026-2034 (USD Billion)
| By End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adults | XX.x | XX.x | XX.x | 2.18 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Fitness Users | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Clinical Weight Management | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Korea Weight Loss Diet Market By Distribution Channel 2026-2034 (USD Billion)
| By Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Online Platforms | XX.x | XX.x | XX.x | 1.97 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nutrition Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Health Stores | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Korea Weight Loss Diet Market By Price Range 2026-2034 (USD Billion)
| By Price Range | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Economy | XX.x | XX.x | XX.x | 1.86 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Mid-Range | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Premium Clinical | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.